Your browser is no longer supported. Please, upgrade your browser.
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.46 Insider Own5.80% Shs Outstand109.29M Perf Week-6.35%
Market Cap189.43M Forward P/E- EPS next Y-0.93 Insider Trans2.02% Shs Float81.03M Perf Month-30.31%
Income-144.90M PEG- EPS next Q-0.30 Inst Own49.10% Short Float5.23% Perf Quarter-51.51%
Sales117.10M P/S1.62 EPS this Y-2.80% Inst Trans-11.17% Short Ratio3.32 Perf Half Y-63.73%
Book/sh1.39 P/B1.27 EPS next Y24.40% ROA-37.90% Target Price7.50 Perf Year-87.01%
Cash/sh0.83 P/C2.14 EPS next 5Y- ROE-85.90% 52W Range1.70 - 15.00 Perf YTD-84.00%
Dividend- P/FCF- EPS past 5Y-13.40% ROI-42.00% 52W High-88.20% Beta0.56
Dividend %- Quick Ratio2.10 Sales past 5Y59.60% Gross Margin31.70% 52W Low4.12% ATR0.13
Employees593 Current Ratio2.50 Sales Q/Q-9.00% Oper. Margin- RSI (14)21.85 Volatility7.01% 7.05%
OptionableYes Debt/Eq0.99 EPS Q/Q25.00% Profit Margin- Rel Volume1.84 Prev Close1.78
ShortableYes LT Debt/Eq0.94 EarningsNov 04 BMO Payout- Avg Volume1.28M Price1.77
Recom2.40 SMA20-17.60% SMA50-31.14% SMA200-57.74% Volume2,344,117 Change-0.56%
Mar-02-21Downgrade Truist Buy → Hold $6
Mar-02-21Downgrade SVB Leerink Outperform → Mkt Perform $22 → $5
Mar-02-21Downgrade Oppenheimer Outperform → Perform
Mar-02-21Downgrade JP Morgan Overweight → Neutral $7
Mar-01-21Downgrade Needham Buy → Hold
Feb-10-21Initiated Evercore ISI Outperform
Oct-26-20Initiated SVB Leerink Outperform $22
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Nov-30-21 08:00AM  
Nov-29-21 08:00AM  
Nov-22-21 08:00AM  
Nov-19-21 01:51PM  
Nov-18-21 08:00AM  
Nov-15-21 07:12AM  
Nov-09-21 08:00AM  
Nov-07-21 09:30AM  
Nov-04-21 10:45AM  
09:15AM  
07:00AM  
Nov-03-21 07:24AM  
Nov-02-21 07:37AM  
Oct-22-21 04:05PM  
Oct-21-21 08:00AM  
Oct-18-21 08:15AM  
Oct-14-21 08:07AM  
Oct-12-21 10:00AM  
Oct-11-21 08:00AM  
Sep-27-21 08:00AM  
Sep-16-21 08:04AM  
02:30AM  
Sep-15-21 08:00AM  
Aug-06-21 07:30PM  
Aug-05-21 08:45AM  
07:00AM  
Aug-04-21 02:22AM  
Jul-26-21 10:02AM  
07:00AM  
Jul-22-21 08:47AM  
Jul-20-21 10:28AM  
Jul-19-21 10:51AM  
Jul-06-21 07:00AM  
Jun-28-21 12:48PM  
Jun-07-21 02:57PM  
Jun-04-21 09:05AM  
May-21-21 09:55AM  
09:21AM  
May-17-21 07:00AM  
May-07-21 05:00PM  
May-06-21 09:35AM  
07:00AM  
06:15AM  
May-05-21 05:12PM  
08:48AM  
08:13AM  
07:00AM  
04:51AM  
May-04-21 05:04PM  
May-03-21 05:31PM  
04:00PM  
12:15PM  
12:00PM  
11:00AM  
10:39AM  
10:00AM  
10:00AM  
09:00AM  
08:39AM  
06:30AM  
12:45AM  
May-02-21 09:15PM  
02:30PM  
10:45AM  
03:37AM  
May-01-21 05:37PM  
09:30AM  
07:40AM  
Apr-30-21 09:00PM  
06:16PM  
04:30PM  
03:14PM  
01:45PM  
01:27PM  
11:50AM  
11:00AM  
09:50AM  
06:30AM  
12:40AM  
Apr-29-21 06:04PM  
04:31PM  
03:15PM  
02:49PM  
01:16PM  
11:45AM  
11:45AM  
11:00AM  
10:25AM  
10:00AM  
06:11AM  
Apr-28-21 10:09PM  
10:00PM  
09:04PM  
03:30PM  
02:30PM  
02:00PM  
01:29PM  
12:00PM  
11:25AM  
11:00AM  
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 22Buy1.843,0005,5203,274,959Nov 22 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 18Buy1.873,0005,6103,271,959Nov 18 04:34 PM
Kanfer JordanDirectorNov 17Buy2.024,95210,0039,586Nov 18 04:29 PM
WU JINNDirectorNov 17Buy2.0330,00060,900443,208Nov 17 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 16Buy2.063,0006,1803,268,959Nov 16 04:16 PM
Kwan RudolfEVP, Chief Medical OfficerNov 16Buy2.054,0008,200173,648Nov 17 04:20 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 15Buy2.125,00010,6003,265,959Nov 15 04:24 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 12Buy2.0710,00020,6903,260,959Nov 12 04:41 PM
WU JINNDirectorOct 01Buy2.6710,00026,700413,208Oct 13 04:37 PM
WU JINNDirectorSep 14Buy3.2250,000161,000403,208Sep 14 05:05 PM
Kwan RudolfEVP, Chief Medical OfficerMay 07Option Exercise4.5524,000109,200167,768May 07 04:58 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMay 07Option Exercise4.555,00022,7503,247,959May 07 04:46 PM
VIERLING JOHNDirectorMay 07Buy4.502501,1253,750May 10 04:19 PM
VIERLING JOHNDirectorMay 06Buy4.041,7006,8633,500May 10 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMay 06Buy3.995,00019,9503,242,959May 06 07:12 PM
CAMPBELL KIMDirectorMay 06Buy4.031,7507,05210,000May 07 04:13 PM
WU JINNDirectorMay 05Option Exercise4.5550,000227,500353,208May 05 05:33 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMay 05Option Exercise4.5525,000113,7503,237,959May 05 05:24 PM
CAMPBELL KIMDirectorApr 05Buy4.428,25036,4658,250Apr 07 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 22Option Exercise4.5510,00045,5003,212,959Mar 22 04:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Option Exercise4.5520,00091,0003,202,959Mar 19 04:12 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 17Option Exercise4.5520,00091,0003,182,959Mar 17 05:02 PM
Zuo William WeiPresident, China DivisionMar 04Sale4.52419,9311,898,088142,883Mar 08 04:39 PM
WU JINNDirectorMar 03Sale4.7598,000465,500303,208Mar 04 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 09Option Exercise4.5510,00045,5003,162,959Dec 09 05:21 PM